Pedro J Cabrales

List of Publications by Year
in descending order

289 papers	7,659 citations	57758 44 h-index	79698 73 g-index
297 all docs	297 docs citations	297 times ranked	7234 citing authors

#	Article	IF	Citations
1	The Disconnect Between Extracorporeal Circulation and the Microcirculation: A Review. ASAIO Journal, 2022, 68, 881-889.	1.6	7
2	Extracorporeal circulation impairs microcirculation perfusion and organ function. Journal of Applied Physiology, 2022, 132, 794-810.	2.5	6
3	Attenuating ischemia-reperfusion injury with polymerized albumin. Journal of Applied Physiology, 2022, 132, 489-496.	2.5	3
4	Nitric oxide releasing nanoparticles reduce inflammation in a small animal model of ARDS. Biomedicine and Pharmacotherapy, 2022, 148, 112705.	5.6	3
5	Implications of microvascular dysfunction and nitric oxide mediated inflammation in severe COVID-19 infection. American Journal of the Medical Sciences, 2022, 364, 251-256.	1.1	2
6	Apohemoglobinâ€haptoglobin (Apohbâ€Hp) Complex as a Vasculoâ€protective Agent in Hypoxia Induced Vasoâ€occlusion in Sickle Cell Disease. FASEB Journal, 2022, 36, .	0.5	0
7	Hyperspectral Wide-Field-Of-View Imaging to Study Dynamic Microcirculatory Changes During Hypoxia. American Journal of Physiology - Heart and Circulatory Physiology, 2022, , .	3.2	1
8	The small molecule NLRP3 inhibitor RRx-001 potentiates regorafenib activity and attenuates regorafenib-induced toxicity in mice bearing human colorectal cancer xenografts.. American Journal of Cancer Research, 2022, 12, 1912-1918.	1.4	0
9	Safety profile of high molecular weight polymerized hemoglobins. Transfusion, 2021, 61, 212-224.	1.6	8
10	Resuscitation from hemorrhagic shock after traumatic brain injury with polymerized hemoglobin. Scientific Reports, 2021, 11, 2509.	3.3	18
11	RRx-001, a downregulator of the CD47- SIRPÎ± checkpoint pathway, does not cause anemia or thrombocytopenia. Expert Opinion on Drug Metabolism and Toxicology, 2021, 17, 355-357.	3.3	10
12	In small cell lung cancer patients treated with RRx-001, a downregulator of CD47, decreased expression of PD-L1 on circulating tumor cells significantly correlates with clinical benefit. Translational Lung Cancer Research, 2021, 10, 274-278.	2.8	8
13	Negative pressure increases microvascular perfusion during severe hemorrhagic shock. Microvascular Research, 2021, 134, 104125.	2.5	2
14	Application of negative tissue interstitial pressure improves functional capillary density after hemorrhagic shock in the absence of volume resuscitation. Physiological Reports, 2021, 9, e14783.	1.7	2
15	Purification and analysis of a protein cocktail capable of scavenging cellâ€free hemoglobin, heme, and iron. Transfusion, 2021, 61, 1894-1907.	1.6	4
16	RRx-001 Increases Erythrocyte Preferential Adhesion to the Tumor Vasculature. International Journal of Molecular Sciences, 2021, 22, 4713.	4.1	4
17	High fat high sucrose diet-induced dyslipidemia in guinea pigs. Journal of Applied Physiology, 2021, 130, 1226-1234.	2.5	5
18	Human polymerized hemoglobin as an alternative to blood in resuscitation from hemorrhagic shock. FASEB Journal, 2021, 35, .	0.5	0

#	Article	IF	Citations
19	Quantifying the Reduction in Microcirculation Perfusion After Extracorporeal Circulation. FASEB Journal, 2021, 35, .	0.5	0
20	Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development. Journal of Medicinal Chemistry, 2021, 64, 7261-7271.	6.4	16
21	Red Blood Cells: Tethering, Vesiculation, and Disease in Micro-Vascular Flow. Diagnostics, 2021, 11, 971.	2.6	6
22	Polymerized albumin restores impaired hemodynamics in endotoxemia and polymicrobial sepsis. Scientific Reports, 2021, 11, 10834.	3.3	6
23	Vascular priming with RRx-001 to increase the uptake and accumulation of temozolomide and irinotecan in orthotopically implanted gliomas. Journal of Drug Targeting, 2021, 29, 998-1003.	4.4	8
24	Increased hemoglobin affinity for oxygen with GBT1118 improves hypoxia tolerance in sickle cell mice. American Journal of Physiology - Heart and Circulatory Physiology, 2021, 321, H400-H411.	3.2	7
25	The RBC's road to ghost and removal: splenic clearance. Blood Advances, 2021, 5, 4422-4425.	5.2	1
26	Heme Scavenging with Apohemoglobin-Haptoglobin Complex in Beta Thalassemia Intermedia Improves Anemia and Iron Indices: A Novel Therapeutic Approach. Blood, 2021, 138, 3082-3082.	1.4	0
27	Itaconate modulates tricarboxylic acid and redox metabolism to mitigate reperfusion injury. Molecular Metabolism, 2020, 32, 122-135.	6.5	83
28	Transfusion of Anaerobically or Conventionally Stored Blood After Hemorrhagic Shock. Shock, 2020, 53, 352-362.	2.1	28
29	Control of systemic inflammation through early nitric oxide supplementation with nitric oxide releasing nanoparticles. Free Radical Biology and Medicine, 2020, 161, 15-22.	2.9	12
30	Desperate Times, Desperate Measures: The Case for RRx-001 in the Treatment of COVID-19. Seminars in Oncology, 2020, 47, 305-308.	2.2	10
31	Polymerized human hemoglobin facilitated modulation of tumor oxygenation is dependent on tumor oxygenation status and oxygen affinity of the hemoglobin-based oxygen carrier. Scientific Reports, 2020, 10, 11372.	3.3	16
32	Apohemoglobin-haptoglobin complexes attenuate the hypertensive response to low-molecular-weight polymerized hemoglobin. Blood Advances, 2020, 4, 2739-2750.	5.2	5
33	Resuscitation After Hemorrhagic Shock in the Microcirculation: Targeting Optimal Oxygen Delivery in the Design of Artificial Blood Substitutes. Frontiers in Medicine, 2020, 7, 585638.	2.6	7
34	What determines blood viscosity at the highest city in the world?. Journal of Physiology, 2020, 598, 3817-3818.	2.9	1
35	Purification ofLumbricus terrestrisMega-Hemoglobin for Diverse Oxygen Therapeutic Applications. ACS Biomaterials Science and Engineering, 2020, 6, 4957-4968.	5.2	7
36	Resuscitation From Hemorrhagic Shock With Fresh and Stored Blood and Polymerized Hemoglobin. Shock, 2020, 54, 464-473.	2.1	15

#	Article	IF	Citations
37	Tumor vascular status controls oxygen delivery facilitated by infused polymerized hemoglobins with varying oxygen affinity. PLoS Computational Biology, 2020, 16, e1008157.	3.2	5
38	Polymerized Hemoglobin With Increased Molecular Size Reduces Toxicity in Healthy Guinea Pigs. ACS Applied Bio Materials, 2020, 3, 2976-2985.	4.6	13
39	Balance between oxygen transport and blood rheology during resuscitation from hemorrhagic shock with polymerized bovine hemoglobin. Journal of Applied Physiology, 2020, 129, 97-107.	2.5	7
40	Enhanced Photodynamic Therapy Using the Apohemoglobin-Haptoglobin Complex as a Carrier of Aluminum Phthalocyanine. ACS Applied Bio Materials, 2020, 3, 4495-4506.	4.6	4
41	Numerical Model for the Determination of Erythrocyte Mechanical Properties and Wall Shear Stress in vivo From Intravital Microscopy. Frontiers in Physiology, 2020, 10, 1562.	2.8	6
42	A Review on Microvascular Hemodynamics. Critical Care Clinics, 2020, 36, 293-305.	2.6	15
43	Apohemoglobin-haptoglobin complex attenuates the pathobiology of circulating acellular hemoglobin and heme. American Journal of Physiology - Heart and Circulatory Physiology, 2020, 318, H1296-H1307.	3.2	12
44	Effects of Increased Hemoglobin Oxygen Affinity on Cerebrovascular Reserve Capacity in Sickle Cell Disease. FASEB Journal, 2020, 34, 1-1.	0.5	0
45	Visualization of the consequences of Succinate Dehydrogenase Inhibition on Oxygen utilization During Hemorrhagic Shock using Hyperspectral Imaging. FASEB Journal, 2020, 34, 1-1.	0.5	0
46	Implications of Systemic Hematocrit on the Radial Distribution of Red Cells in Arterioles. FASEB Journal, 2020, 34, 1-1.	0.5	0
47	Correlation of decreased expression of PD-L1 on circulating tumor cells and clinical benefit in SCLC Patients treated with RRx-001, a CD47 downregulator, in a phase II trial.. Journal of Clinical Oncology, 2020, 38, 9062-9062.	1.6	0
48	Cardiovascular effects of polymerized hemoglobin in a dyslipidemia model. FASEB Journal, 2020, 34, 1-1.	0.5	0
49	Polymerized Hemoglobin Maintains Cardiac Function After Extreme Anemia. FASEB Journal, 2020, 34, 1-1.	0.5	0
50	Apoâ€hemoglobin and Haptoglobin Limit Acellular Hemoglobin Negative Effects. FASEB Journal, 2020, 34, 1-1.	0.5	0
51	Resuscitation from Hemorrhagic Shock after Traumatic Brain Injury with Polymerized Hemoglobin. FASEB Journal, 2020, 34, 1-1.	0.5	0
52	Polymerized human hemoglobin increases the effectiveness of cisplatin-based chemotherapy in non-small cell lung cancer. Oncotarget, 2020, 11, 3770-3781.	1.8	7
53	Prediction of Recovery From Severe Hemorrhagic Shock Using Logistic Regression. IEEE Journal of Translational Engineering in Health and Medicine, 2019, 7, 1-9.	3.7	6
54	RRx-001 protects normal tissues but not tumors via Nrf2 induction and Bcl-2 inhibition. Journal of Cancer Research and Clinical Oncology, 2019, 145, 2045-2050.	2.5	10

#	Article	IF	Citations
55	Hepatocyte-specific HIF-1Î± ablation improves obesity-induced glucose intolerance by reducing first-pass GLP-1 degradation. Science Advances, 2019, 5, eaaw4176.	10.3	20
56	Response by Lundberg et al to Letter Regarding Article, â€œHemoglobin Î²93 Cysteine Is Not Required for Export of Nitric Oxide Bioactivity From the Red Blood Cellâ€• Circulation, 2019, 140, e760-e761.	1.6	0
57	Reducing Ischemia/Reperfusion Injury by the Targeted Delivery of Nitric Oxide from Magnetic-Field-Induced Localization of S-Nitrosothiol-Coated Paramagnetic Nanoparticles. ACS Applied Bio Materials, 2019, 2, 2907-2919.	4.6	10
58	Cardioprotective Effect of Phase 3 Clinical Anticancer Agent, RRx-001, in Doxorubicin-Induced Acute Cardiotoxicity in Mice. Molecular Pharmaceutics, 2019, 16, 2929-2934.	4.6	12
59	Hemoglobin Î²93 Cysteine Is Not Required for Export of Nitric Oxide Bioactivity From the Red Blood Cell. Circulation, 2019, 139, 2654-2663.	1.6	42
60	Doxorubicin-loaded red blood cells reduced cardiac toxicity and preserved anticancer activity. Drug Delivery, 2019, 26, 433-442.	5.7	32
61	Red Blood Cell Metabolic Responses to Torpor and Arousal in the Hibernator Arctic Ground Squirrel. Journal of Proteome Research, 2019, 18, 1827-1841.	3.7	34
62	RRx-001 Acts as a Dual Small Molecule Checkpoint Inhibitor by Downregulating CD47 on Cancer Cells and SIRP-Î± on Monocytes/Macrophages. Translational Oncology, 2019, 12, 626-632.	3.7	66
63	Increased Hemoglobin Oxygen Affinity With 5-Hydroxymethylfurfural Supports Cardiac Function During Severe Hypoxia. Frontiers in Physiology, 2019, 10, 1350.	2.8	13
64	Nitrite may serve as a combination partner and a biomarker for the anti-cancer activity of RRx-001. Biorheology, 2019, 56, 221-235.	0.4	3
65	CX3CL1-Fc treatment prevents atherosclerosis in Ldlr KO mice. Molecular Metabolism, 2019, 20, 89-101.	6.5	21
66	Knockdown of ANT2 reduces adipocyte hypoxia and improves insulin resistance in obesity. Nature Metabolism, 2019, 1, 86-97.	11.9	71
67	Pharmacological Increase of Hb-O2 Affinity with a Voxelotor Analog Does Not Decrease Brain Tissue pO2 or Limit O2 Extraction in Brain Tissues of Sickle Cell Mice. Blood, 2019, 134, 3564-3564.	1.4	4
68	RRx-001 is a phase III aerospace-derived small molecule that immunonormalizes the tumor microenvironment.. Journal of Clinical Oncology, 2019, 37, 156-156.	1.6	1
69	A Review of Clinical Radioprotection and Chemoprotection for Oral Mucositis. Translational Oncology, 2018, 11, 771-778.	3.7	63
70	GBT440 improves red blood cell deformability and reduces viscosity of sickle cell blood under deoxygenated conditions. Clinical Hemorheology and Microcirculation, 2018, 70, 95-105.	1.7	58
71	Do Skeletal Dynamics Mediate Sugar Uptake and Transport in Human Erythrocytes?. Biophysical Journal, 2018, 114, 1440-1454.	0.5	3
72	Emergent behaviors in RBCs flows in micro-channels using digital particle image velocimetry. Microvascular Research, 2018, 116, 77-86.	2.5	7

#	Article	IF	Citations
73	Navigating the â€œNo Man's Landâ€•of TKI-Failed EGFR-Mutated Nonâ€“Small Cell Lung Cancer (NSCLC): A Review. Neoplasia, 2018, 20, 92-98.	5.3	24
74	Brief report: RRx-001 is a c-Myc inhibitor that targets cancer stem cells. Oncotarget, 2018, 9, 23439-23442.	1.8	17
75	Erythrocyte Aging, Protection via Vesiculation: An Analysis Methodology via Oscillatory Flow. Frontiers in Physiology, 2018, 9, 1607.	2.8	26
76	Enzyme promiscuity drives branched-chain fatty acid synthesis in adipose tissues. Nature Chemical Biology, 2018, 14, 1021-1031.	8.0	165
77	Implications Enzymatic Degradation of the Endothelial Glycocalyx on the Microvascular Hemodynamics and the Arteriolar Red Cell Free Layer of the Rat Cremaster Muscle. Frontiers in Physiology, 2018, 9, 168.	2.8	19
78	Quantitative analysis of spatial irregularities in RBCs flows. Chaos, Solitons and Fractals, 2018, 115, 349-355.	5.1	5
79	Platelet inhibitory effects of the Phase 3 anticancer and normal tissue cytoprotective agent, RR xâ€001. Journal of Cellular and Molecular Medicine, 2018, 22, 5076-5082.	3.6	11
80	Cardiac-specific knockout and pharmacological inhibition of Endothelin receptor type B lead to cardiac resistance to extreme hypoxia. Journal of Molecular Medicine, 2018, 96, 975-982.	3.9	10
81	Rrx-001 Is a Phase 3 Small Molecule Dual Inhibitor of CD47 and SirpÎ± with Activity in Multiple Myeloma. Blood, 2018, 132, 5623-5623.	1.4	3
82	Use of Logistic Regression to Determine Parameter Ability for Recovery Prediction in Experimental Rat Hemorrhagic Shock Model. FASEB Journal, 2018, 32, lb338.	0.5	0
83	Resuscitation from Hemorrhagic Shock with High Molecular Weight Polymerized Hemoglobin. FASEB Journal, 2018, 32, lb337.	0.5	0
84	Posttransfusion Increase of Hematocrit per se Does Not Improve Circulatory Oxygen Delivery due to Increased Blood Viscosity. Anesthesia and Analgesia, 2017, 124, 1547-1554.	2.2	28
85	RRx-001 protects against cisplatin-induced toxicities. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1671-1677.	2.5	18
86	The macrophage stimulating anti-cancer agent, RRx-001, protects against ischemia-reperfusion injury. Expert Review of Hematology, 2017, 10, 575-582.	2.2	13
87	GBT1118, a potent allosteric modifier of hemoglobin O₂affinity, increases tolerance to severe hypoxia in mice. American Journal of Physiology - Heart and Circulatory Physiology, 2017, 313, H381-H391.	3.2	28
88	RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials. Expert Opinion on Investigational Drugs, 2017, 26, 109-119.	4.1	45
89	Blood Quality Diagnostic Device Detects Storage Differences Between Donors. IEEE Transactions on Biomedical Circuits and Systems, 2017, 11, 1400-1405.	4.0	7
90	RRx-001 Priming of PD-1 Inhibition in the Treatment of Small Cell Carcinoma of the Vagina: A Rare Gynecological Tumor. Case Reports in Oncology, 2017, 10, 276-280.	0.7	6

#	Article	IF	Citations
91	Rat red blood cell storage lesions in various additive solutions. Clinical Hemorheology and Microcirculation, 2017, 67, 45-57.	1.7	9
92	Prospects for Human Erythrocyte Skeleton-Bilayer Dissociation during Splenic Flow. Biophysical Journal, 2017, 113, 900-912.	0.5	26
93	Acute kidney function and morphology following topload administration of recombinant hemoglobin solution. Artificial Cells, Nanomedicine and Biotechnology, 2017, 45, 24-30.	2.8	1
94	Cardiac function during resuscitation from hemorrhagic shock with polymerized bovine hemoglobin-based oxygen therapeutic. Artificial Cells, Nanomedicine and Biotechnology, 2017, 45, 686-693.	2.8	10
95	Role of glycocalyx in attenuation of shear stress on endothelial cells: From in vivo experiments to microfluidic circuits. , 2017, , .		1
96	DPIV analysis of RBCs flows in serpentine micro-channel. , 2017, , .		0
97	RRx-001 Reset: Chemoresensitization via NO-Mediated M1 Macrophage Repolarization. , 2017, , 35-56.		1
98	Abstract 966: Phase II clinical trial patient responses to the macrophage activating agent RRx-001 correlate to TGF- î² pathway activation and markers for fibrosis. , 2017, , .		2
99	Polyethylene Glycol Camouflaged Earthworm Hemoglobin. PLoS ONE, 2017, 12, e0170041.	2.5	18
100	Mixtures of tense and relaxed state polymerized human hemoglobin regulate oxygen affinity and tissue construct oxygenation. PLoS ONE, 2017, 12, e0185988.	2.5	20
101	Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets. Case Reports in Oncology, 2016, 9, 285-289.	0.7	12
102	Turning on the Radio: Epigenetic Inhibitors as Potential Radiopriming Agents. Biomolecules, 2016, 6, 32.	4.0	9
103	Targeting tumor hypoxia with the epigenetic anticancer agent, RRx-001: a superagonist of nitric oxide generation. Medical Oncology, 2016, 33, 85.	2.5	11
104	Partial Response to Platinum Doublets in Refractory EGFR-Positive Non-Small Cell Lung Cancer Patients after RRx-001: Evidence of Episensitization. Case Reports in Oncology, 2016, 9, 62-67.	0.7	16
105	Conversion of Platinum-Etoposide-Resistant to Sensitive SCLC after Treatment with the Epi-Immunotherapeutic RRx-001: A Case Report. Oncology Research and Treatment, 2016, 39, 720-723.	1.2	6
106	Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC. Respiratory Medicine Case Reports, 2016, 18, 62-65.	0.4	10
107	Immunoresponsive Gene 1 and Itaconate Inhibit Succinate Dehydrogenase to Modulate Intracellular Succinate Levels. Journal of Biological Chemistry, 2016, 291, 14274-14284.	3.4	342
108	A look inside the mechanistic black box: Are red blood cells the critical effectors of RRx-001 cytotoxicity?. Medical Oncology, 2016, 33, 63.	2.5	15

#	Article	IF	Citations
109	Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001. Case Reports in Oncology, 2016, 9, 164-170.	0.7	15
110	Control of overweight and obesity in childhood through education in meal time habits. The â€˜good manners for a healthy futureâ€™ programme. Pediatric Obesity, 2016, 11, 484-490.	2.8	21
111	Senp1 drives hypoxia-induced polycythemia via GATA1 and Bcl-xL in subjects with Mongeâ€™s disease. Journal of Experimental Medicine, 2016, 213, 2729-2744.	8.5	29
112	RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets. Case Reports in Oncology, 2016, 9, 171-176.	0.7	11
113	A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient after Priming with RRx-001. Clinical Medicine Insights: Oncology, 2016, 10, CMO.S40429.	1.3	12
114	Hyperthermia during exercise â€“ a double-edged sword. Temperature, 2016, 3, 512-513.	3.0	3
115	Increases in core temperature counterbalance effects of haemoconcentration on blood viscosity during prolonged exercise in the heat. Experimental Physiology, 2016, 101, 332-342.	2.0	23
116	RRx-001, A novel dinitroazetidine radiosensitizer. Investigational New Drugs, 2016, 34, 371-377.	2.6	37
117	Inflammatory response to implantation of transparent nanocrystalline yttria-stabilized zirconia using a dorsal window chamber model. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 1757-1763.	3.3	17
118	RRx-001, an epigenetic-based radio- and chemosensitizer, has vascular normalizing effects on SCCVII and U87 tumors. Clinical Epigenetics, 2016, 8, 53.	4.1	20
119	Poly(ethylene glycol) hydrogels with cell cleavable groups for autonomous cell delivery. Biomaterials, 2016, 77, 186-197.	11.4	57
120	Notch-independent RBPJ controls angiogenesis in the adult heart. Nature Communications, 2016, 7, 12088.	12.8	43
121	Abstract 2165: Enhanced uptake and accumulation of temozolomide and irinotecan in orthotopically-implanted gliomas by vascular priming with RRx-001. Cancer Research, 2016, 76, 2165-2165.	0.9	2
122	Rockets, radiosensitizers, and RRx-001: an origin story part I. Discovery Medicine, 2016, 21, 173-80.	0.5	16
123	RRx-001, a novel clinical-stage chemosensitizer, radiosensitizer, and immunosensitizer, inhibits glucose 6-phosphate dehydrogenase in human tumor cells. Discovery Medicine, 2016, 21, 251-65.	0.5	16
124	Perfusion pressure and blood flow determine microvascular apparent viscosity. Experimental Physiology, 2015, 100, 977-987.	2.0	12
125	Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine Tumor. Case Reports in Oncology, 2015, 8, 461-465.	0.7	13
126	From METS to malaria: RRx-001, a multi-faceted anticancer agent with activity in cerebral malaria. Malaria Journal, 2015, 14, 218.	2.3	15

#	Article	IF	Citations
127	NO supplementation for transfusion medicine and cardiovascular applications. Future Science OA, 2015, 1, .	1.9	5
128	Red blood cells flows in rectilinear microfluidic chip. , 2015, 2015, 3225-8.		0
129	Evaluating the Capacity to Generate and Preserve Nitric Oxide Bioactivity in Highly Purified Earthworm Erythrocruorin. Journal of Biological Chemistry, 2015, 290, 99-117.	3.4	12
130	Endothelin receptor B, a candidate gene from human studies at high altitude, improves cardiac tolerance to hypoxia in genetically engineered heterozygote mice. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 10425-10430.	7.1	45
131	Impact of hemoglobin nitrite to nitric oxide reductase on blood transfusion for resuscitation from hemorrhagic shock. Asian Journal of Transfusion Science, 2015, 9, 55.	0.3	15
132	Effect of oxygenated polyethylene glycol decorated hemoglobin on microvascular diameter and functional capillary density in the transgenic mouse model of sickle cell anemia. Artificial Cells, Nanomedicine and Biotechnology, 2015, 43, 10-17.	2.8	3
133	Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study. Lancet Oncology, The, 2015, 16, 1133-1142.	10.7	76
134	Influence of serological factors and BMI on the blood pressure/hematocrit association in healthy young men and women. Vascular Health and Risk Management, 2014, 10, 271.	2.3	3
135	Nitric Oxide Synthase Inhibition Attenuates Cardiac Response to Hemodilution with Viscogenic Plasma Expander. Korean Circulation Journal, 2014, 44, 105.	1.9	1
136	Replacing the Transfusion of 1â€"2 Units of Blood with Plasma Expanders that Increase Oxygen Delivery Capacity: Evidence from Experimental Studies. Journal of Functional Biomaterials, 2014, 5, 232-245.	4.4	5
137	Topically Applied NO-Releasing Nanoparticles Can Increase Intracorporal Pressure and Elicit Spontaneous Erections in a Rat Model of Radical Prostatectomy. Journal of Sexual Medicine, 2014, 11, 2903-2914.	0.6	22
138	Microhemodynamic aberrations created by transfusion of stored blood. Transfusion, 2014, 54, 1015-1027.	1.6	43
139	Microhemodynamic parameters quantification from intravital microscopy videos. Physiological Measurement, 2014, 35, 351-367.	2.1	17
140	Resuscitation from hemorrhagic shock using polymerized hemoglobin compared to blood. American Journal of Emergency Medicine, 2014, 32, 248-255.	1.6	25
141	Localized increase of tissue oxygen tension by magnetic targeted drug delivery. Nanotechnology, 2014, 25, 265102.	2.6	7
142	Abstract 1420: RRx-001 inhibits glucose erythrocyte and tumor glucose 6-phosphate dehydrogenase. Cancer Research, 2014, 74, 1420-1420.	0.9	5
143	GTx011, an Anti-Sickling Compound, Improves SS Blood Rheology By Reduction of HbS polymerization Via Allosteric Modulation of O2 Affinity. Blood, 2014, 124, 1370-1370.	1.4	8
144	Plasma expander and blood storage effects on capillary perfusion in transfusion after hemorrhage. Transfusion, 2013, 53, 49-59.	1.6	7

#	Article	IF	Citations
145	Comparison of video image edge detection operators on red blood cells in microvasculature. , 2013, , .		7
146	Two-phase model for prediction of cell-free layer width in blood flow. Microvascular Research, 2013, 85, 68-76.	2.5	7
147	Improving cardiac function with new-generation plasma volume expanders. American Journal of Emergency Medicine, 2013, 31, 54-63.	1.6	6
148	Nitric Oxide Synthase Dysfunction Contributes to Impaired Cerebroarteriolar Reactivity in Experimental Cerebral Malaria. PLoS Pathogens, 2013, 9, e1003444.	4.7	49
149	Blood Substitutes. ASAIO Journal, 2013, 59, 337-354.	1.6	66
150	Effect of deformability difference between two erythrocytes on their aggregation. Physical Biology, 2013, 10, 036001.	1.8	18
151	Hemorheological implications of perfluorocarbon based oxygen carrier interaction with colloid plasma expanders and blood. Biotechnology Progress, 2013, 29, 796-807.	2.6	13
152	Transport of nitric oxide by perfluorocarbon emulsion. Biotechnology Progress, 2013, 29, 1565-1572.	2.6	8
153	Examining and Mitigating Acellular Hemoglobin Vasoactivity. Antioxidants and Redox Signaling, 2013, 18, 2329-2341.	5.4	18
154	Cerebral tissue oxygenation impairment during experimental cerebral malaria. Virulence, 2013, 4, 686-697.	4.4	19
155	Effects of Fibrinogen Concentrate After Shock/Resuscitation. Critical Care Medicine, 2013, 41, e301-e308.	0.9	12
156	HBOC Vasoactivity: Interplay Between Nitric Oxide Scavenging and Capacity to Generate Bioactive Nitric Oxide Species. Antioxidants and Redox Signaling, 2013, 18, 2284-2297.	5.4	16
157	HBOC Vasoactivity: Interplay Between Nitric Oxide Scavenging and Capacity to Generate Bioactive Nitric Oxide Species. Antioxidants and Redox Signaling, 2013, 18, 2284-2297.	5.4	31
158	The Role of Blood and Plasma Viscosity in Restoring Oxygen Delivery Capacity. , 2013, , 75-93.		0
159	Increased hemoglobin O₂affinity protects during acute hypoxia. American Journal of Physiology - Heart and Circulatory Physiology, 2012, 303, H271-H281.	3.2	33
160	PEG-albumin supraplasma expansion is due to increased vessel wall shear stress induced by blood viscosity shear thinning. American Journal of Physiology - Heart and Circulatory Physiology, 2012, 302, H2489-H2497.	3.2	26
161	Reduction of Oxygen-Carrying Capacity Weakens the Effects of Increased Plasma Viscosity on Cardiac Performance in Anesthetized Hemodilution Model. ISRN Anesthesiology, 2012, 2012, 1-9.	0.3	0
162	Impact of Enzymatic Degradation of the Endothelial Glycocalyx on Vascular Permeability in an Awake Hamster Model. Critical Care Research and Practice, 2012, 2012, 1-8.	1.1	16

#	Article	IF	Citations
163	Hemoglobin Encapsulated Poly(Ethylene Glycol) Surface Conjugated Vesicles Attenuate Vasoactivity of Cell-Free Hemoglobin. Current Drug Discovery Technologies, 2012, 9, 224-234.	1.2	3
164	Autoregulation and mechanotransduction control the arteriolar response to small changes in hematocrit. American Journal of Physiology - Heart and Circulatory Physiology, 2012, 303, H1096-H1106.	3.2	32
165	The effects of acute nitric oxide synthase inhibition on systemic circulation and organ blood flow. , 2012, , .		0
166	A nanoparticle delivery vehicle for S-nitroso-N-acetyl cysteine: Sustained vascular response. Nitric Oxide - Biology and Chemistry, 2012, 27, 150-160.	2.7	31
167	Exogenous intravascular nitric oxide enhances ventricular function after hemodilution with plasma expander. Life Sciences, 2012, 90, 39-46.	4.3	3
168	Small-volume resuscitation from hemorrhagic shock with polymerized human serum albumin. American Journal of Emergency Medicine, 2012, 30, 1336-1346.	1.6	12
169	Oxygen delivery during extreme anemia with ultra-pure earthworm hemoglobin. Life Sciences, 2012, 91, 852-859.	4.3	19
170	S-nitrosoglutathione Prevents Experimental Cerebral Malaria. Journal of NeuroImmune Pharmacology, 2012, 7, 477-487.	4.1	28
171	Simulation of NO and O2 transport facilitated by polymerized hemoglobin solutions in an arteriole that takes into account wall shear stress-induced NO production. Biophysical Chemistry, 2012, 162, 45-60.	2.8	6
172	Hypervolemic infusion of Lumbricus terrestris erythrocruorin purified by tangentialâ€flow filtration. Transfusion, 2012, 52, 1729-1740.	1.6	32
173	Effects of Acute Anemia and Hyperoxia on Oxygen Distribution. Advances in Experimental Medicine and Biology, 2012, 737, 213-218.	1.6	4
174	Effect of Systemic Hematocrit on Blood Velocity Profiles in Arterioles. FASEB Journal, 2012, 26, 859.3.	0.5	0
175	Nitric Oxide Synthase Inhibition Weakens Beneficial Effects of Increased Plasma Viscosity on Cardiac Function in Hemodilution Model. FASEB Journal, 2012, 26, 864.8.	0.5	0
176	Delaying Blood Transfusion in Experimental Acute Anemia with a Perfluorocarbon Emulsion. Anesthesiology, 2011, 114, 901-911.	2.5	18
177	Plasma expander viscosity effects on red cell-free layer thickness after moderate hemodilution. Biorheology, 2011, 48, 277-291.	0.4	12
178	Small-Volume Resuscitation From Hemorrhagic Shock Using High-Molecular-Weight Tense-State Polymerized Hemoglobins. Journal of Trauma, 2011, 71, 798-807.	2.3	8
179	Cardiac Systolic Function Recovery After Hemorrhage Determines Survivability During Shock. Journal of Trauma, 2011, 70, 787-793.	2.3	10
180	Improved Resuscitation From Hemorrhagic Shock With Ringer's Lactate With Increased Viscosity in the Hamster Window Chamber Model. Journal of Trauma, 2011, 71, 418-424.	2.3	10

#	Article	IF	Citations
181	Nonlinear cardiovascular regulation consequent to changes in blood viscosity. Clinical Hemorheology and Microcirculation, 2011, 49, 29-36.	1.7	29
182	Exogenous nitric oxide prevents cardiovascular collapse during hemorrhagic shock. Resuscitation, 2011, 82, 607-613.	3.0	33
183	Exogenous nitric oxide decreases brain vascular inflammation, leakage and venular resistance during Plasmodium berghei ANKA infection in mice. Journal of Neuroinflammation, 2011, 8, 66.	7.2	50
184	Integration of cardiovascular regulation by the blood/endothelium cellâ€free layer. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2011, 3, 458-470.	6.6	18
185	Synthesis and biophysical properties of polymerized human serum albumin. Biotechnology Progress, 2011, 27, 290-296.	2.6	15
186	Synthesis, biophysical properties, and oxygenation potential of variable molecular weight glutaraldehydeâ€polymerized bovine hemoglobins with low and high oxygen affinity. Biotechnology Progress, 2011, 27, 1172-1184.	2.6	25
187	Nitric Oxide Protection Against Murine Cerebral Malaria Is Associated With Improved Cerebral Microcirculatory Physiology. Journal of Infectious Diseases, 2011, 203, 1454-1463.	4.0	86
188	Nanoengineering bactericidal nitric oxide therapies. Virulence, 2011, 2, 185-187.	4.4	7
189	Biophysical Properties and Oxygenation Potential of High-Molecular-Weight Glutaraldehyde-Polymerized Human Hemoglobins Maintained in the Tense and Relaxed Quaternary States. Tissue Engineering - Part A, 2011, 17, 927-940.	3.1	19
190	Reversal of hemoglobin-induced vasoconstriction with sustained release of nitric oxide. American Journal of Physiology - Heart and Circulatory Physiology, 2011, 300, H49-H56.	3.2	72
191	Cardiac Performance during Acute Hemmorrhagic Shock in Pentobarbital-Anesthetized Hamsters using Left Ventricular Pressure-Volume Measurement. , 2011, , .		0
192	Nitric oxide prevents cardiovascular collapse during shock. FASEB Journal, 2011, 25, lb478.	0.5	0
193	Nitric Oxide from Nanoparticles and Applications to Cardiovascular Health. , 2011, , 407-426.		0
194	Intravital Microscopy of the Mouse Brain Microcirculation using a Closed Cranial Window. Journal of Visualized Experiments, 2010, , .	0.3	27
195	Sustained release nitric oxide from long-lived circulating nanoparticles. Free Radical Biology and Medicine, 2010, 49, 530-538.	2.9	75
196	Nitric Oxide Protects Against Cerebral Malaria. Free Radical Biology and Medicine, 2010, 49, S110.	2.9	0
197	Low Oxygen-Affinity Hemoglobin Solution Increases Oxygenation of Partially Ischemic Tissue During Acute Anemia. Journal of the American College of Surgeons, 2010, 210, 271-279.	0.5	6
198	Synthesis, biophysical properties and pharmacokinetics of ultrahigh molecular weight tense and relaxed state polymerized bovine hemoglobins. Biomaterials, 2010, 31, 3723-3735.	11.4	35

#	Article	IF	Citations
199	Cardiac mechanoenergetic cost of elevated plasma viscosity after moderate hemodilution. Biorheology, 2010, 47, 225-237.	0.4	10
200	Effects of plasma viscosity modulation on cardiac function during moderate hemodilution. Asian Journal of Transfusion Science, 2010, 4, 102.	0.3	13
201	The Physics of Oxygen Delivery: Facts and Controversies. Antioxidants and Redox Signaling, 2010, 12, 683-691.	5.4	10
202	Cardiovascular benefits in moderate increases of blood and plasma viscosity surpass those associated with lowering viscosity: Experimental and clinical evidence. Clinical Hemorheology and Microcirculation, 2010, 44, 75-85.	1.7	76
203	Blood pressure directly correlates with blood viscosity in diabetes type 1 children but not in normals. Clinical Hemorheology and Microcirculation, 2010, 44, 55-61.	1.7	27
204	The variability of blood pressure due to small changes of hematocrit. American Journal of Physiology - Heart and Circulatory Physiology, 2010, 299, H863-H867.	3.2	29
205	Tissue oxygenation after exchange transfusion with ultrahigh-molecular-weight tense- and relaxed-state polymerized bovine hemoglobins. American Journal of Physiology - Heart and Circulatory Physiology, 2010, 298, H1062-H1071.	3.2	19
206	Tissue oxidative metabolism after extreme hemodilution with PEG-conjugated hemoglobin. Journal of Applied Physiology, 2010, 109, 1852-1859.	2.5	4
207	Perfusion vs. oxygen delivery in transfusion with â€œfreshâ€•and â€œoldâ€•red blood cells: The experimental evidence. Transfusion and Apheresis Science, 2010, 43, 69-78.	1.0	91
208	Murine Cerebral Malaria Is Associated with a Vasospasm-Like Microcirculatory Dysfunction, and Survival upon Rescue Treatment Is Markedly Increased by Nimodipine. American Journal of Pathology, 2010, 176, 1306-1315.	3.8	96
209	CARDIAC PERFORMANCE DURING ACUTE HEMORRHAGIC SHOCK IN PENTOBARBITAL-ANESTHETIZED HAMSTERS USING LEFT VENTRICULAR PRESSURE-VOLUME MEASUREMENT. , 2010, , .		0
210	Low dose nitrite enhances perfusion after fluid resuscitation from hemorrhagic shock. FASEB Journal, 2010, 24, 591.17.	0.5	0
211	Hematocrit and mean arterial blood pressure in pre- and postmenopause women. Vascular Health and Risk Management, 2009, 5, 483.	2.3	8
212	Effects of the molecular mass of tense-state polymerized bovine hemoglobin on blood pressure and vasoconstriction. Journal of Applied Physiology, 2009, 107, 1548-1558.	2.5	60
213	Preferential capillary channels exist in the microcirculation. Journal of the American College of Surgeons, 2009, 209, S39.	0.5	0
214	Hexa-thiocarbamoyl Phenyl PEG5K Hb: Vasoactivity and Structure. Protein Journal, 2009, 28, 199-212.	1.6	11
215	Exogenous nitric oxide induces protection during hemorrhagic shock. Resuscitation, 2009, 80, 707-712.	3.0	30
216	Low dose nitrite enhances perfusion after fluid resuscitation from hemorrhagic shock. Resuscitation, 2009, 80, 1431-1436.	3.0	12

#	Article	IF	Citations
217	Will fixing the vasoactivity caused by hemoglobin-based oxygen carriers be enough?*. Critical Care Medicine, 2009, 37, 2125-2126.	0.9	2
218	POLYMERIZED BOVINE HEMOGLOBIN CAN IMPROVE SMALL-VOLUME RESUSCITATION FROM HEMORRHAGIC SHOCK IN HAMSTERS. Shock, 2009, 31, 300-307.	2.1	25
219	MICROCIRCULATORY EFFECTS OF CHANGING BLOOD HEMOGLOBIN OXYGEN AFFINITY DURING HEMORRHAGIC SHOCK RESUSCITATION IN AN EXPERIMENTAL MODEL. Shock, 2009, 31, 646-653.	2.1	33
220	Microvascular benefits of increasing plasma viscosity and maintaining blood viscosity: Counterintuitive experimental findings. Biorheology, 2009, 46, 167-179.	0.4	52
221	Increased plasma viscosity prolongs microhemodynamic conditions during small volume resuscitation from hemorrhagic shock. Resuscitation, 2008, 77, 379-386.	3.0	39
222	Volume resuscitation from hemorrhagic shock with albumin and hexaPEGylated human serum albumin. Resuscitation, 2008, 79, 139-146.	3.0	28
223	Microvascular experimental evidence on the relative significance of restoring oxygen carrying capacity vs. blood viscosity in shock resuscitation. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2008, 1784, 1421-1427.	2.3	41
224	Balance between vasoconstriction and enhanced oxygen delivery. Transfusion, 2008, 48, 2087-2095.	1.6	20
225	Survival time in severe hemorrhagic shock after perioperiative hemodilution scenario with polyethylene glycol conjugated human serum albumin is longer than with HES 130/0.4: a microvascular perspective. Critical Care, 2008, 12, R54.	5.8	22
226	Lowering of Blood Pressure by Increasing Hematocrit with Nonâ€“Nitric Oxideâ€“Scavenging Red Blood Cells. American Journal of Respiratory Cell and Molecular Biology, 2008, 38, 135-142.	2.9	32
227	Isovolemic exchange transfusion with increasing concentrations of low oxygen affinity hemoglobin solution limits oxygen delivery due to vasoconstriction. American Journal of Physiology - Heart and Circulatory Physiology, 2008, 295, H2212-H2218.	3.2	19
228	Modulation of Perfusion and Oxygenation by Red Blood Cell Oxygen Affinity during Acute Anemia. American Journal of Respiratory Cell and Molecular Biology, 2008, 38, 354-361.	2.9	27
229	Oxygen transport during hemodilution with a perfluorocarbon-based oxygen carrier: effect of altitude and hyperoxia. Journal of Applied Physiology, 2008, 105, 588-594.	2.5	5
230	Blood pressure reduction due to hemoglobin glycosylation in type 2 diabetic patients. Vascular Health and Risk Management, 2008, Volume 4, 917-922.	2.3	7
231	Nonobese, exercising children diagnosed with dyslipidemia have normal C-reactive protein. Vascular Health and Risk Management, 2008, , 65.	2.3	1
232	Increased hematocrit and reduced blood pressure following control of glycemia in diabetes. Clinical Hemorheology and Microcirculation, 2008, 38, 57-64.	1.7	4
233	Effects of erythrocyte flexibility on microvascular perfusion and oxygenation during acute anemia. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 293, H1206-H1215.	3.2	67
234	Deferoxamine Lowers Tissue Damage After 80% Exchange Transfusion with Polymerized Hemoglobin. Antioxidants and Redox Signaling, 2007, 9, 375-384.	5.4	18

#	Article	IF	Citations
235	Time-Dependant Oxygen Partial Pressure in Capillaries and Tissue in the Hamster Window Chamber Model. Antioxidants and Redox Signaling, 2007, 9, 845-853.	5.4	8
236	Microvascular and capillary perfusion following glycocalyx degradation. Journal of Applied Physiology, 2007, 102, 2251-2259.	2.5	98
237	RESUSCITATION FROM HEMORRHAGIC SHOCK WITH HYDROXYETHYL STARCH AND COAGULATION CHANGES. Shock, 2007, 28, 461-467.	2.1	28
238	IS RESUSCITATION FROM HEMORRHAGIC SHOCK LIMITED BY BLOOD OXYGEN-CARRYING CAPACITY OR BLOOD VISCOSITY?. Shock, 2007, 27, 380-389.	2.1	67
239	Microvascular and systemic effects following top load administration of saturated carbon monoxide-saline solution*. Critical Care Medicine, 2007, 35, 1123-1132.	0.9	40
240	Perfluorocarbons as gas transporters for O₂, NO, CO and volatile anesthetics. Transfusion Alternatives in Transfusion Medicine, 2007, 9, 294-303.	0.2	12
241	Resuscitation from hemorrhagic shock: recovery of oxygen carrying capacity or perfusion? Efficacy of new plasma expanders. Transfusion Alternatives in Transfusion Medicine, 2007, 9, 246-253.	0.2	9
242	Pegylated hemoglobins mechanisms to avoid vasoconstriction and maintain perfusion. Transfusion Alternatives in Transfusion Medicine, 2007, 9, 281-293.	0.2	15
243	Terminal Lymphatics: The Potential â€œLethal Cornerâ€•in the Distribution of Tissue pO₂. Lymphatic Research and Biology, 2007, 5, 159-168.	1.1	14
244	New phosphorescence quenching oxygen measurements technique yields unusual tissue and plasma Po2 distributions. Journal of Applied Physiology, 2007, 102, 2081-2082.	2.5	5
245	Hemorrhagic shock resuscitation with carbon monoxide saturated blood. Resuscitation, 2007, 72, 306-318.	3.0	52
246	Transfusion restores blood viscosity and reinstates microvascular conditions from hemorrhagic shock independent of oxygen carrying capacity. Resuscitation, 2007, 75, 124-134.	3.0	66
247	Perfluorocarbon in Microcirculation During Ischemia Reperfusion. Journal of the American College of Surgeons, 2007, 204, 225-235.	0.5	18
248	Excessive Erythrocytosis Does Not Elevate Capillary Oxygen Delivery in Subcutaneous Mouse Tissue. Microcirculation, 2007, 14, 111-123.	1.8	11
249	Nitric oxide regulation of microvascular oxygen exchange during hypoxia and hyperoxia. Journal of Applied Physiology, 2006, 100, 1181-1187.	2.5	41
250	Oxygen release from arterioles with normal flow and no-flow conditions. Journal of Applied Physiology, 2006, 100, 1569-1576.	2.5	16
251	Dissociation of local nitric oxide concentration and vasoconstriction in the presence of cell-free hemoglobin oxygen carriers. Blood, 2006, 108, 3603-3610.	1.4	149
252	TRANSFUSION WITH POLYMERIZED HEMOGLOBIN COMPROMIZED TISSUE VIABILITY. ASAIO Journal, 2006, 52, 13A.	1.6	0

#	Article	IF	Citations
253	Microvascular effects following treatment with polyethylene glycol-albumin in lipopolysaccharide-induced endotoxemia. Critical Care Medicine, 2006, 34, 108-117.	0.9	55
254	Can the effects of vasoactivity of molecular hemoglobin-based plasma expanders be ignored?*. Critical Care Medicine, 2006, 34, 1566-1567.	0.9	4
255	The vascular wall as a regulator of tissue oxygenation. Current Opinion in Nephrology and Hypertension, 2006, 15, 67-71.	2.0	18
256	Mechanotransduction and the homeostatic significance of maintaining blood viscosity in hypotension, hypertension and haemorrhage. Journal of Internal Medicine, 2006, 259, 364-372.	6.0	70
257	Blood viscosity maintains microvascular conditions during normovolemic anemia independent of blood oxygen-carrying capacity. American Journal of Physiology - Heart and Circulatory Physiology, 2006, 291, H581-H590.	3.2	73
258	Increased cardiac output and microvascular blood flow during mild hemoconcentration in hamster window model. American Journal of Physiology - Heart and Circulatory Physiology, 2006, 291, H310-H317.	3.2	29
259	Plasma viscosity regulates systemic and microvascular perfusion during acute extreme anemic conditions. American Journal of Physiology - Heart and Circulatory Physiology, 2006, 291, H2445-H2452.	3.2	89
260	MICROVASCULAR PERSPECTIVE OF OXYGEN-CARRYING AND -NONCARRYING BLOOD SUBSTITUTES. Annual Review of Biomedical Engineering, 2006, 8, 289-321.	12.3	24
261	Mechanisms of Oxygen Transport in the Microcirculation: Effects of Cell-Free Oxygen Carriers. , 2006, , 84-92.		1
262	Shear Stress Mechanotransduction and the Flow Properties of Blood. , 2006, , 93-101.		0
263	Deferoxamine Lowers Tissue Damage After 80% Exchange Transfusion with Polymerized Hemoglobin. Antioxidants and Redox Signaling, 2006, .	5.4	0
264	Blood viscosity: A factor in tissue survival?*. Critical Care Medicine, 2005, 33, 1662-1663.	0.9	13
265	Role of endothelial nitric oxide in microvascular oxygen delivery and consumption. Free Radical Biology and Medicine, 2005, 39, 1229-1237.	2.9	58
266	Extreme hemodilution with PEG-hemoglobin vs. PEG-albumin. American Journal of Physiology - Heart and Circulatory Physiology, 2005, 289, H2392-H2400.	3.2	37
267	Oxygen transport by low and normal oxygen affinity hemoglobin vesicles in extreme hemodilution. American Journal of Physiology - Heart and Circulatory Physiology, 2005, 288, H1885-H1892.	3.2	46
268	Microvascular oxygen delivery and consumption following treatment with verapamil. American Journal of Physiology - Heart and Circulatory Physiology, 2005, 288, H1515-H1520.	3.2	21
269	Alginate plasma expander maintains perfusion and plasma viscosity during extreme hemodilution. American Journal of Physiology - Heart and Circulatory Physiology, 2005, 288, H1708-H1716.	3.2	58
270	Oxygen release from low and normal P50 Hb vesicles in transiently occluded arterioles of the hamster window model. American Journal of Physiology - Heart and Circulatory Physiology, 2005, 288, H2897-H2903.	3.2	27

#	Article	IF	Citations
271	Effect of oxygen consumption by measuring method on Po2 transients associated with the passage of erythrocytes in capillaries of rat mesentery. American Journal of Physiology - Heart and Circulatory Physiology, 2005, 289, H1777-H1779.	3.2	9
272	Elevated plasma viscosity in extreme hemodilution increases perivascular nitric oxide concentration and microvascular perfusion. American Journal of Physiology - Heart and Circulatory Physiology, 2005, 288, H1730-H1739.	3.2	196
273	Effects of extreme hemodilution with hemoglobin-based O2 carriers on microvascular pressure. American Journal of Physiology - Heart and Circulatory Physiology, 2005, 288, H2146-H2153.	3.2	49
274	EARLY DIFFERENCE IN TISSUE PH AND MICROVASCULAR HEMODYNAMICS IN HEMORRHAGIC SHOCK RESUSCITATION USING POLYETHYLENE GLYCOL-ALBUMIN- AND HYDROXYETHYL STARCH-BASED PLASMA EXPANDERS. Shock, 2005, 24, 66-73.	2.1	47
275	Increase plasma viscosity sustains microcirculation after resuscitation from hemorrhagic shock and continuous bleeding. Shock, 2005, 23, 549-55.	2.1	54
276	Radial displacement of red blood cells during hemodilution and the effect on arteriolar oxygen profile. American Journal of Physiology - Heart and Circulatory Physiology, 2004, 286, H1223-H1228.	3.2	11
277	Microlymphatic and tissue oxygen tension in the rat mesentery. American Journal of Physiology - Heart and Circulatory Physiology, 2004, 286, H878-H883.	3.2	35
278	Oxygen-carrying blood substitutes: a microvascular perspective. Expert Opinion on Biological Therapy, 2004, 4, 1147-1157.	3.1	13
279	Oxygen Distribution and Respiration by the Microcirculation. Antioxidants and Redox Signaling, 2004, 6, 1011-1018.	5.4	30
280	Oxygen delivery and consumption in the microcirculation after extreme hemodilution with perfluorocarbons. American Journal of Physiology - Heart and Circulatory Physiology, 2004, 287, H320-H330.	3.2	62
281	Microvascular pressure and functional capillary density in extreme hemodilution with low- and high-viscosity dextran and a low-viscosity Hb-based O2 carrier. American Journal of Physiology - Heart and Circulatory Physiology, 2004, 287, H363-H373.	3.2	122
282	Increased tissue Po2and decreased O2delivery and consumption after 80% exchange transfusion with polymerized hemoglobin. American Journal of Physiology - Heart and Circulatory Physiology, 2004, 287, H2825-H2833.	3.2	52
283	Microvascular Po2during extreme hemodilution with hemoglobin site specifically PEGylated at Cys-93(Î²) in hamster window chamber. American Journal of Physiology - Heart and Circulatory Physiology, 2004, 287, H1609-H1617.	3.2	22
284	Microvascular perfusion upon exchange transfusion with stored red blood cells in normovolemic anemic conditions. Transfusion, 2004, 44, 1626-1634.	1.6	169
285	HYPEROSMOTIC-HYPERONCOTIC VERSUS HYPEROSMOTIC-HYPERVISCOUS: SMALL VOLUME RESUSCITATION IN HEMORRHAGIC SHOCK. Shock, 2004, 22, 431-437.	2.1	48
286	RESUSCITATION FROM HEMORRHAGIC SHOCK WITH MalPEG-ALBUMIN: COMPARISON WITH MalPEG-HEMOGLOBIN. Shock, 2004, 22, 351-357.	2.1	24
287	Measurement of the cardiac output in small animals by thermodilution. Microvascular Research, 2003, 66, 77-82.	2.5	27
288	Microvascular oxygen distribution in awake hamster window chamber model during hyperoxia. American Journal of Physiology - Heart and Circulatory Physiology, 2003, 285, H1537-H1545.	3.2	408

#	Article	IF	Citations
289	Microcirculatory changes during chronic adaptation to hypoxia. American Journal of Physiology - Heart and Circulatory Physiology, 2003, 285, H2064-H2071.	3.2	45